List of works - Ugo De Giorgi

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

scientific article

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

scientific article published on 18 December 2017

Plasma AR and abiraterone-resistant prostate cancer.

scientific article

Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study

scientific article published on March 31, 2014

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

scientific article published on 17 February 2014

Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy

scientific article published on October 18, 2010

Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

scientific article published on 15 June 2011

Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database

scientific article published on 28 March 2011

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

scientific article published on 09 May 2019

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

scientific article

Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer

scientific article

Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells

scientific article published on November 28, 2010

Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer

scientific article published on 21 April 2016

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

scientific article published on December 15, 2014

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

scientific article published on 30 May 2018

Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination

scientific article

Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies

scientific article

Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

scientific article published on 09 July 2016

High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer

scientific article published on 19 September 2014

A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients

scientific article

Germ cell tumours of the testis

scientific article

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.

scientific article published on 13 October 2016

Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors.

scientific article

18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer

scientific article published on 21 July 2010

Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer

scientific article published on 15 May 2012

(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.

scientific article published on 26 March 2015

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.

scientific article published on 13 May 2016

Androgen receptor signaling pathways as a target for breast cancer treatment

scientific article

Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone

scientific article published on 8 May 2014

Cell-free DNA as a diagnostic marker for cancer: current insights

scientific article

Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide

scientific article published on 27 September 2014

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.

scientific article published on 25 October 2014

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

scientific article published on 23 July 2018

PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis

scientific article

Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma

scientific article published on 18 July 2014

Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy

scientific article published on 6 January 2015

Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials

scientific article

Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.

scientific article

Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

scientific article

PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer

scientific article published on 12 June 2014

Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors

scientific article published on 4 December 2014

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group

scientific article published on 12 October 2015

Perspectives on mTOR inhibitors for castration-refractory prostate cancer.

scientific article published on October 2012

Circulating tumor cells in newly diagnosed inflammatory breast cancer

scientific article

Immunotherapy for Prostate Cancer: Where We Are Headed

scientific article

GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications

scientific article published on 10 August 2016

Systemic immune-inflammation index in germ-cell tumours

scientific article published on 27 February 2018

Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor

scientific article published on 23 May 2006

Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.

scientific article published on 07 February 2014

Urinary RNA-based biomarkers for prostate cancer detection.

scientific article published on 11 August 2017

List of works by Ugo De Giorgi

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Plasma AR and abiraterone-resistant prostate cancer.

Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy

Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer

Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells

Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination

Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies

Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer

A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients

Germ cell tumours of the testis

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.

Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors.

18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer

Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer

(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.

Androgen receptor signaling pathways as a target for breast cancer treatment

Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone

Cell-free DNA as a diagnostic marker for cancer: current insights

Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis

Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma

Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy

Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials

Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.

Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer

Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group

Perspectives on mTOR inhibitors for castration-refractory prostate cancer.

Circulating tumor cells in newly diagnosed inflammatory breast cancer

Immunotherapy for Prostate Cancer: Where We Are Headed

GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications

Systemic immune-inflammation index in germ-cell tumours

Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor

Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.

Urinary RNA-based biomarkers for prostate cancer detection.